Regional Analysis

Global Opioid Use Disorder Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global opioid use disorder market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. The market is expected to witness significant growth in the near future, owing to increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players. For instance, in December 2021, Camurus AB, a pharmaceutical company, announced that its U.S. licensee Braeburn had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its updated New Drug Application (NDA) for Brixadi (buprenorphine) extended-release injections for the treatment of opioid use disorder. The CRL is a result of continued quality related deficiencies at Braeburn’s U.S. based third party manufacturer, identified by the FDA during a pre-approval inspection.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa